

DIFFERENCES IN TREATMENT DURATION IN PANCREATIC CANCER PATIENTS TREATED WITH CHEMOTHERAPY FROM 2005 TO 2014

B Reques-Sastre , L Reques-Sastre, R Diez-Fernández, T Molina-García.
Hospital Universitario de Getafe, Madrid.

1 BACKGROUND

Pancreatic cancer has a poor prognosis being palliative treatment the goal of treatment for most patients. Clinical trials with new drugs and regimens have shown a slight increase in survival in recent years.


2 PURPOSE

To compare chemotherapy treatment duration in pancreatic cancer patients in two 5-year periods, 2005-2009 and 2010-2014.

3 MATERIAL AND METHODS

Study	Design	Descriptive longitudinal
	Period	January 2005- December 2014

INCLUSION CRITERIA
All pancreatic cancer patients treated with chemotherapy between 2005 and 2014




ANALYSIS	
Quantitative variables	Student's t test
qualitative variables	Chi-square test
Difference in treatment duration	log rank test

4 RESULTS

Sociodemographic data	Women: 50.9%	N=116
	Age: 63.7 (IQR = 56-72)	

No statistically significant differences were found in sex (**p = 0.679**) or age (**p = 0.09**) between the two study periods.

Differences in the treatment duration were found depending on period, from 91 [84,119] days before 2010 to 175 [136, 241] days after 2010. Survival curve of treatment duration showed significant differences depending on the period: (p=0.02).



5 CONCLUSIONS

Chemotherapy treatment duration in pancreatic cancer patients has been significantly prolonged in recent years. This might be due to the development of new drugs. Whether this is associated with an increase in survival needs to be confirmed in further studies.

Conflict of interest: Nothing to disclose

Email: berta.reques@salud.madrid.org